| Category | Key facts | Supporting evidence |
|---|---|---|
| Definition | Hereditary intrinsic factor deficiency (IFD), also called congenital intrinsic factor deficiency or hereditary juvenile cobalamin deficiency due to **GIF**, is a rare inherited disorder of selective vitamin B12 absorption caused by absent/dysfunctional gastric intrinsic factor, leading to cobalamin deficiency and typically megaloblastic anemia in childhood. | OMIM noted as **#261000** in case literature; defined as a rare inherited cause of B12 deficiency due to **GIF** mutations (pqac-00000001, pqac-00000005). PNAS 2005 established GIF mutations as cause of hereditary juvenile cobalamin deficiency: DOI https://doi.org/10.1073/pnas.0500517102 (pqac-00000000, pqac-00000006). Blood 2004 first molecular proof of inherited IF deficiency: DOI https://doi.org/10.1182/blood-2003-07-2239 (pqac-00000007, pqac-00000015). |
| Gene / inheritance | Causal gene: **GIF** (gastric intrinsic factor gene; chromosome 11q12). Inheritance is **autosomal recessive**; affected patients generally have biallelic pathogenic variants, while parents are heterozygous carriers. | “all patients … were homozygous, whereas their respective parents were heterozygous,” supporting AR inheritance (PNAS 2005; DOI https://doi.org/10.1073/pnas.0500517102) (pqac-00000006). Ruan 2020 reports compound heterozygous **c.776delA** and **c.585C>A** in a Chinese patient (DOI https://doi.org/10.1186/s12881-020-01158-z) (pqac-00000005). Ferrand 2015 reports compound heterozygosity **c.79+1G>A** and **c.973delG** (DOI https://doi.org/10.1007/8904_2014_351) (pqac-00000001). |
| Core mechanism | Normal physiology: intrinsic factor (IF), secreted by gastric parietal cells, binds vitamin B12 after haptocorrin degradation in the duodenum; the **IF–B12** complex is absorbed in the ileum through the **cubam receptor** composed of **cubilin (CUBN)** and **amnionless (AMN)**. In GIF deficiency, lack of functional IF prevents IF–B12 complex formation and causes selective intestinal B12 malabsorption. | GIF encodes IF, “a 417-aa protein secreted by gastric parietal cells that binds cobalamin” (PNAS 2005; DOI https://doi.org/10.1073/pnas.0500517102) (pqac-00000006). 2024 review summarizes that only the **IF–vitamin B12 complex** is recognized by **cubam** on ileal enterocytes; cubam consists of **CUBN + AMN** (DOI https://doi.org/10.3390/ijms25158021) (pqac-00000011, pqac-00000012, pqac-00000016). |
| Typical onset / natural history | Usually presents in **infancy or early childhood**; recurrent or progressive anemia is common. Untreated disease may cause failure to thrive, neurologic injury, and can be fatal, but prognosis is excellent with timely lifelong B12 replacement. | Ferrand 2015: congenital IFD “presents in infancy or early childhood” with low serum cobalamin and megaloblastic anemia (DOI https://doi.org/10.1007/8904_2014_351) (pqac-00000001). Ruan 2020 case had recurrent severe anemia from age 2 (DOI https://doi.org/10.1186/s12881-020-01158-z) (pqac-00000005). PNAS 2005 notes inherited cobalamin malabsorption can be fatal untreated (DOI https://doi.org/10.1073/pnas.0500517102) (pqac-00000000). |
| Key phenotypes | Hallmark phenotype is **megaloblastic/macrocytic anemia**. Other reported features: pancytopenia, weakness/fatigue, jaundice, failure to thrive, feeding/GI symptoms, hepatosplenomegaly, peripheral neuropathy, and variable neurologic manifestations. | Macrocytosis example MCV **111.6 fL** and very low B12 in Chaldean cases (JIMD Rep 2013; DOI https://doi.org/10.1007/8904_2012_133) (pqac-00000002). Ferrand 2015 lists pancytopenia, splenomegaly, hepatomegaly, peripheral neuropathy, GI symptoms, infantile death (pqac-00000001). Ruan 2020 notes severity ranging from weakness to life-threatening anemia, jaundice, and neurologic abnormalities (pqac-00000005). |
| Diagnostic biomarkers / tests | Typical lab pattern: **low serum vitamin B12**, often **elevated methylmalonic acid (MMA)** and **elevated homocysteine**; macrocytosis/megaloblastic marrow and sometimes elevated C3/acylcarnitine-related markers. Historical functional test: **Schilling/radiocobalamin absorption**. Genetic confirmation by **GIF sequencing** is now preferred. | Ferrand 2015 example: serum B12 **61 pmol/L** (ref 198–615), homocysteine **16.7 µmol/L**, methylmalonic aciduria, elevated C3 (DOI https://doi.org/10.1007/8904_2014_351) (pqac-00000001). 2024 review: impaired B12 metabolism raises **MMA** and **homocysteine**, important diagnostic markers (DOI https://doi.org/10.3390/ijms25158021) (pqac-00000012). Tanner 2012 recommends low serum Cbl plus elevated homocysteine/MMA and molecular analysis of **CUBN, AMN, GIF**; Schilling test has been retired (DOI https://doi.org/10.1186/1750-1172-7-56) (pqac-00000010). |
| Distinguishing from Imerslund–Gräsbeck syndrome (IGS) | IFD phenocopies IGS hematologically, but **proteinuria is usually absent** in IFD and common in IGS. Historically, low B12 absorption in IFD is **corrected by added intrinsic factor** on radiocobalamin testing, whereas IGS is **not corrected** because the cubam receptor is defective. | Tanner 2012: IGS usually presents with **proteinuria**, “which is not observed in IFD” (DOI https://doi.org/10.1186/1750-1172-7-56) (pqac-00000010). PNAS 2005: inherited IFD should be distinguished from IGS because radiocobalamin absorption with IF **corrects** low absorption in IFD (pqac-00000006). JIMD 2013 case emphasized absence of proteinuria and lack of Schilling response details for IFD workup (pqac-00000002). |
| Gastric / autoimmune findings | Unlike autoimmune pernicious anemia, hereditary IFD usually has **normal gastroscopy/gastric acid secretion** and **negative intrinsic-factor antibodies**. | Ruan 2020: patients “usually present with cobalamin deficiency without gastroscopy abnormality and intrinsic factor antibodies” (DOI https://doi.org/10.1186/s12881-020-01158-z) (pqac-00000004, pqac-00000005). Yassin 2004 documented normal gastric acid output despite severe IF deficiency (DOI https://doi.org/10.1182/blood-2003-07-2239) (pqac-00000015). |
| Treatment / real-world management | Standard care is **lifelong vitamin B12 replacement**, usually **parenteral hydroxocobalamin or cyanocobalamin**. Hematologic and biochemical response is typically rapid and robust; early treatment helps prevent irreversible neurologic sequelae. Some reports describe successful oral therapy in selected patients, but IM therapy remains standard. | Ruan 2020: intramuscular vitamin B12 normalized hemoglobin; example initial dosing **0.5 mg every other day** (pqac-00000005). Sturm 2013: monthly **hydroxocobalamin 1,000 mcg** resolved clinical issues (pqac-00000002). Abdallah 2012: life-long parenteral Cbl is lifesaving; in 7 patients, **1 mg twice yearly** maintained normal clinical, hematologic, and metabolic parameters after stabilization (DOI https://doi.org/10.1016/j.ymgme.2012.07.007) (pqac-00000008). Ferrand 2015: oral or parenteral B12 led to complete recovery (pqac-00000001). |
| Prognosis | With prompt recognition and replacement therapy, patients can remain healthy long term; delay risks persistent neurologic damage. | Tanner 2012: “Early diagnosis improves the lifelong care required by these patients and prevents potential neurological long-term complications” (abstract summarized in evidence) (DOI https://doi.org/10.1186/1750-1172-7-56) (pqac-00000010). Abdallah 2012 and multiple case reports show durable normalization under maintenance B12 (pqac-00000008, pqac-00000001, pqac-00000005). |
| Founder effects / populations | Population-specific founder variants have been reported. Examples include a **West-African founder mutation**, a **Chaldean/Iraqi founder mutation c.1073+5G>A**, and a treatable cluster in the **Old Order Mennonite** population of southwestern Ontario. A 2020 report described the **first East Asian** genetically confirmed case. | Ament 2009: juvenile cobalamin deficiency in individuals of African ancestry caused by a founder **GIF** mutation (DOI https://doi.org/10.1111/j.1365-2141.2008.07496.x) (pqac-00000000 via summary, pqac-00000004). Sturm 2013: intronic **c.1073+5G>A** identified as a founder mutation limited to Chaldeans from Iraq (DOI https://doi.org/10.1007/8904_2012_133) (pqac-00000002). Ferrand 2015 describes cases in Old Order Mennonites (DOI https://doi.org/10.1007/8904_2014_351) (pqac-00000001). Ruan 2020 reports first East-Asia mutation-defined case (pqac-00000005). |
| Key statistics | In the largest screening study of suspected hereditary cobalamin malabsorption, pathogenic variants were identified in **126/154 unrelated cases (82%)**. Among solved cases, **28/126 (22%)** had **GIF** mutations; **53/126 (42%)** had **CUBN** and **45/126 (36%)** had **AMN** variants. The study reported **52 novel defects**, including **7 novel GIF** variants. | Tanner 2012, Orphanet J Rare Dis: 154 families/patients screened; 126 solved (**82%**); **22% GIF**, **42% CUBN**, **36% AMN**; **52** novel defects total, **7 in GIF** (DOI https://doi.org/10.1186/1750-1172-7-56) (pqac-00000010). |
| Recent developments (2023–2024) | No major 2023–2024 disease-specific therapeutic breakthroughs were found; recent progress is mainly in broader **B12 pathway reviews** and continued use of **genetic sequencing** for precise diagnosis. Current understanding reinforces IF–cubam biology and biomarker-based diagnosis (B12, MMA, homocysteine). | 2024 review provides updated pathway synthesis of IF-dependent absorption and downstream trafficking (DOI https://doi.org/10.3390/ijms25158021) (pqac-00000011, pqac-00000012, pqac-00000016). No disease-specific interventional trials for hereditary IFD were identified in the retrieved trial search; management remains replacement therapy informed by established case series (pqac-00000008). |


*Table: This table condenses the main definitional, genetic, mechanistic, diagnostic, treatment, and population-genetic facts for hereditary intrinsic factor deficiency due to GIF. It is designed as a quick-reference evidence map with direct links to the supporting literature and available context IDs.*